Abstract
Background and Methods
As a consequence of the rapid evolution of malaria prophylaxis recommendations throughout the world, the Italian Society of Tropical Medicine (SIMET—Società Italiana di Medicina Tropicale) has set up a working group in charge of preparing a new national guideline. Other scientific societies interested in the topic were also involved in the project.
Results and Conclusions
The group stated that awareness about malaria risk and characteristics, as well as protection from mosquito bites, are recommended for all travellers visiting malaria-endemic countries. The risk and benefit of malaria chemoprophylaxis must be carefully balanced before prescribing drugs: the disease-related risk must outweigh the possibility of drugs’ side effects. As a general rule, malaria pills are the first choice for travellers to high-risk areas, such as sub-Saharan Africa, Eastern India, Myanmar, Eastern Indonesia, Papua New Guinea and, with some limitations, South-East Asia, and the Amazon part of Venezuela, Guyana and French Guyana. However, several other factors, such as itinerary, season, duration of trip, availability of insect bite protection, pre-existing conditions and compliance, must be taken into account. In low-risk areas, stand-by emergency treatment is the first option. In minimal-risk areas and in Plasmodium vivax areas, a prompt diagnosis only is advised (Central America, South America outside the Amazon basin, Middle East, China, Thailand, Nepal). Recommendations may be modified when particular groups of travellers are concerned, such as long-term residents, visiting friends and relatives, patients with pre-existing conditions, pregnant women and children.
Similar content being viewed by others
References
World Health Organization (WHO). International travel and health. 2012. http://www.who.int/ith/en/.
Haut Conseil de la Santé Publique. Recommandations sanitaires pour les voyageurs, 2012 (à l’attention des professionnels de santé). Avis du 16 avril. BEH 20-21/29 mai 2012. http://www.sante.gouv.fr/IMG/pdf/Recommandations_sanitaires_pour_les_voyageurs_2012.pdf.
Centers for Disease Control and Prevention (CDC). The yellow book 2012. Health information for international travel. Atlanta: CDC; 2012.
Deutsche Gesellschaft für Tropenmedizin und Internationale Gesundheit (DTG). Empfehlungen zur Malariavorbeugung. 2012. http://www.dtg.org/uploads/media/Malaria_2012_01.pdf.
Chiodini P, Hill D, Lalloo D, Lea G, Walker E, Whitty C, Bannister B. Guidelines for malaria prevention in travellers from the United Kingdom. London: Health Protection Agency; 2007.
Calleri G, Behrens RH, Bisoffi Z, Bjorkman A, Castelli F, Gascon J, Gobbi F, Grobusch MP, Jelinek T, Schmid ML, Niero M, Caramello P. Variability in malaria prophylaxis prescribing across Europe: a Delphi method analysis. J Travel Med. 2008;15:294–301. doi:10.1111/j.1708-8305.2008.00226.x.
Bisoffi Z, Napoletano G, Castelli F, Romi R. Linee guida per la profilassi antimalarica. Giorn Ital Med Trop. 2003;8:15–30.
Calleri G, Behrens RH, Schmid ML, Gobbi F, Grobusch MP, Castelli F, Gascon J, Bisoffi Z, Jelinek T, Caramello P; TropNetEurop. Malaria chemoprophylaxis recommendations for immigrants to Europe, visiting relatives and friends—a Delphi method study. Malar J. 2011;10;137. doi:10.1186/1475-2875-10-137.
Frickmann H, Schwarz NG, Holtherm HU, Maassen W, Vorderwülbecke F, Erkens K, Fischer M, Morwinsky T, Hagen RM. Compliance with antimalarial chemoprophylaxis in German soldiers: a 6-year survey. Infection. 2013;41:311–20. doi:10.1007/s15010-013-0411-5.
Behrens RH, Carroll B, Hellgren U, Visser LG, Siikamäki H, Vestergaard LS, Calleri G, Jänisch T, Myrvang B, Gascon J, Hatz C. The incidence of malaria in travellers to South-East Asia: is local malaria transmission a useful risk indicator? Malar J. 2010;9:266. doi:10.1186/1475-2875-9-266.
World Health Organization (WHO). Country profiles. http://www.who.int/malaria/publications/country-profiles/en/.
World Health Organization (WHO). World malaria report. Geneva: WHO; 2012.
Rombo L. Who needs drug prophylaxis against malaria? My personal view. J Travel Med. 2005;12:217–21.
Petersen E. Malaria chemoprophylaxis: when should we use it and what are the options? Expert Rev Anti Infect Ther. 2004;2:119–32.
White NJ. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J. 2011;10:297. doi:10.1186/1475-2875-10-297.
Dutto M, Severini F, Romi R. Guida per l’entomoprofilassi. Rapporti ISTISAN 11/24. 2011. http://www.iss.it/binary/publ/cont/11_24_web.pdf.
Franco-Paredes C, Santos-Preciado JI. Problem pathogens: prevention of malaria in travellers. Lancet Infect Dis. 2006;6:139–49.
Schwartz E. Prophylaxis of malaria. Mediterr J Hematol Infect Dis. 2012;4:e2012045. doi:10.4084/MJHID.2012.45.
Jacquerioz FA, Croft AM. Drugs for preventing malaria in travellers. Cochrane Database Syst Rev. 2009;(4):CD006491.
Genton B, D’Acremont V. Malaria prevention in travelers. Infect Dis Clin North Am. 2012;26:637–54. doi:10.1016/j.idc.2012.05.003.
Askling HH, Bruneel F, Burchard G, Castelli F, Chiodini PL, Grobusch MP, Lopez-Vélez R, Paul M, Petersen E, Popescu C, Ramharter M, Schlagenhauf P; European Society for Clinical Microbiology and Infectious Diseases Study Group on Clinical Parasitology. Management of imported malaria in Europe. Malar J. 2012;11:328. doi:10.1186/1475-2875-11-328.
Gething PW, Patil AP, Smith DL, Guerra CA, Elyazar IR, Johnston GL, Tatem AJ, Hay SI. A new world malaria map: Plasmodium falciparum endemicity in 2010. Malar J. 2011;10:378.
Ramharter M, Grobusch MP, Kiessling G, Adegnika AA, Möller U, Agnandji ST, Kramer M, Schwarz N, Kun JF, Oyakhirome S, Issifou S, Borrmann S, Lell B, Mordmüller B, Kremsner PG. Clinical and parasitological characteristics of puerperal malaria. J Infect Dis. 2005;191:1005–9.
McGready R, Ashley EA, Nosten F. Malaria and the pregnant traveller. Travel Med Infect Dis. 2004;2:127–42.
Royal College of Obstetricians and Gynaecologists. The prevention of malaria in pregnancy. Green-top guideline no. 54A. 2010. http://www.rcog.org.uk/files/rcog-corp/GTG54aPreventionMalariaPregnancy0410.pdf.
Schlagenhauf P, Blumentals WA, Suter P, Regep L, Vital-Durand G, Schaerer MT, Boutros MS, Rhein HG, Adamcova M. Pregnancy and fetal outcomes after exposure to mefloquine in the pre- and periconception period and during pregnancy. Clin Infect Dis. 2012;54:e124–31.
Schlagenhauf P, Petersen E. Malaria chemoprophylaxis: strategies for risk groups. Clin Microbiol Rev. 2008;21:466–72.
Matteelli A, Carvalho AC, Bigoni S. Visiting relatives and friends (VFR), pregnant, and other vulnerable travelers. Infect Dis Clin North Am. 2012;26:625–35.
Steffen R, Heusser R, Mächler R, Bruppacher R, Naef U, Chen D, Hofmann AM, Somaini B. Malaria chemoprophylaxis among European tourists in tropical Africa: use, adverse reactions, and efficacy. Bull World Health Organ. 1990;68:313–22.
Romi R, Boccolini D, D’Amato S, Cenci C, Peragallo M, D’Ancona F, Pompa MG, Majori G. Incidence of malaria and risk factors in Italian travelers to malaria endemic countries. Travel Med Infect Dis. 2010;8:144–54. doi:10.1016/j.tmaid.2010.02.001.
Mascarello M, Gobbi F, Angheben A, Concia E, Marocco S, Anselmi M, Monteiro G, Rossanese A, Bisoffi Z. Imported malaria in immigrants to Italy: a changing pattern observed in north eastern Italy. J Travel Med. 2009;16:317–21.
Scolari C, Tedoldi S, Casalini C, Scarcella C, Matteelli A, Casari S, El Hamad I, Castelli F. Knowledge, attitudes, and practices on malaria preventive measures of migrants attending a public health clinic in northern Italy. J Travel Med. 2002;9:160–2.
Joint Formulary Committee. British National Formulary. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2006.
Castelli F, Patroni A. The human immunodeficiency virus-infected traveler. Clin Infect Dis. 2000;31:1403–8.
World Health Organization (WHO). Standards for maternal and neonatal care. Geneva: WHO; 2004.
Abecasis J, Dores H, Arroja I, Santos JM, Silva A. Travelers on beta-blockers: is malaria chemoprophylaxis dangerous? Rev Port Cardiol. 2009;28:1153–9.
Steketee RW, Nahlen BL, Parise ME, Menendez C. The burden of malaria in pregnancy in malaria-endemic areas. Am J Trop Med Hyg. 2001;64:28–35.
Descloux E, De Monbrison F, Basselin C, Vial T, Peyron F. Mefloquine adverse effects with atypical facial lesions in an overweight patient. Travel Med Infect Dis. 2010;8:318–21.
Nayyar GML, Breman JG, Newton PN, Herrington J. Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. Lancet Infect Dis. 2012;12:488–96. doi:10.1016/S1473-3099(12)70064-6.
World Health Organization (WHO). Guidelines for the treatment of malaria. Second edition. Geneva: WHO; 2010. http://www.who.int/malaria/publications/atoz/9789241547925/en/index.html.
Conflict of interest
GC has received grants for speaking by Sigma-Tau; FC has acted as PI for a Sigma-Tau-sponsored trial; IEH, FG, AM, GN, RR, and AR declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Calleri, G., Castelli, F., El Hamad, I. et al. New Italian guidelines for malaria prophylaxis in travellers to endemic areas. Infection 42, 239–250 (2014). https://doi.org/10.1007/s15010-013-0563-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15010-013-0563-3